Telitacicept plus low-dose mycophenolate mofetil in the treatment of IgA nephropathy: a retrospective study
Clinical and Experimental Medicine · 2025
DOI: 10.1007/s10238-025-01829-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2025. Verfasst von Huapan Shu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan, 430060, Hubei, China. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Mycophenolic Acid, Recombinant Fusion Proteins, Immunosuppressive Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Hubei Province Major Scientific and Technological Special Project.
Abstract (Originalsprache)
Presently, no specific therapies have been recognized for immunoglobulin A nephropathy (IgAN). Mycophenolate mofetil (MMF) has been verified effective for Chinese patients with IgAN. Telitacicept is a full-human TACI-FC fusion preventing B cells maturation and activation, and it has been proven to be beneficial for IgAN in a phase II clinical trial. This study was designed to observe the efficacy and safety of telitacicept plus low-dose MMF for IgAN treatment. This retrospective cohort study included 24 patients with IgAN, and patients were treated with telitacicept plus MMF. The primary outcome was settled as the changing in proteinuria and estimated glomerular filtration rate (eGFR). The subordinate outcome was set as the changing in hematuria. The mean follow-up time was 23 months. The median baseline proteinuria was 2.5 (1.74, 6.58) g/d, and eGFR was 94.97 (56.8, 120.67) mL/min/1.73 m2. There were noteworthy reductions in proteinuria at 3, 6, 9, 12, 15, 18, 21 and 24 months when compared to the baseline levels [1.45 (0.78, 1.8) g/d [p = 0.0122], 0.505 (0.26, 0.99) g/d [p < 0.0001], 0.48 (0.28, 0.76) g/d [p < 0.0001], 0.3 (0.17, 0.85) g/d [p < 0.0001], 0.23 (0.18, 0.575) g/d [p < 0.0001], 0.18 (0.12, 0.325) g/d [p < 0.0001], 0.14 (0.105, 0.22) g/d [p < 0.0001] and 0.14 (0.103, 0.278) g/d [p < 0.0001]]. All patients maintained stable eGFR during follow-up times. Besides, telitacicept plus MMF remarkably alleviated the hematuria. Telitacicept plus MMF treatment led to not only remarkable clinically significant reduction in proteinuria and hematuria, but also stable serum creatinine value of patients with IgAN without adverse side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan, 430060, Hubei, China.
- Department of Nephrology, Hubei Provincial Hospital of Traditional Chinese Medicine of Hubei University of Chinese Medicine, Wuhan, China.
- Department of Nephrology, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan, 430060, Hubei, China. chenxh9905@163.com.
Förderung
- National Natural Science Foundation of China
- Hubei Province Major Scientific and Technological Special Project
Zitieren
APA
Shu, H., Wang, Y., Li, X., Zhang, L., Wei, Z., Song, Y., Chen, J., Cheng, H., Chen, C., Liang, W., Wang, H., & Chen, X. (2025). Telitacicept plus low-dose mycophenolate mofetil in the treatment of IgA nephropathy: a retrospective study. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-025-01829-2
Vancouver
Shu H, Wang Y, Li X, Zhang L, Wei Z, Song Y, et al. Telitacicept plus low-dose mycophenolate mofetil in the treatment of IgA nephropathy: a retrospective study. Clinical and Experimental Medicine. 2025. doi:10.1007/s10238-025-01829-2
BibTeX
@article{Shu2025,
author = {Shu, Huapan and Wang, Yujuan and Li, Xiaoqing and Zhang, Lu and Wei, Zhongping and Song, Yuan and Chen, Ju and Cheng, Hui and Chen, Cheng and Liang, Wei and Wang, Huiming and Chen, Xinghua},
title = {Telitacicept plus low-dose mycophenolate mofetil in the treatment of IgA nephropathy: a retrospective study},
journal = {Clinical and Experimental Medicine},
year = {2025},
doi = {10.1007/s10238-025-01829-2}
}
EUVIMED